Table 3.
COVID-19 – summary of World Health Organization (WHO), National Institute of Health, and Infectious Diseases Society of America guidelines (COVID-19 Treatment Guidelines Panel, 2021; Organization, 2021; Bhimraj et al., 2021).
| Drug | WHO | Dose | Patient condition |
|---|---|---|---|
| Baricitinib | N/A | 4 mg daily for 14 days or until hospital discharge (whichever is first) | Patients with SpO2 ≤ 94 % on room air and CRP ≥ 75 mg/L, and no invasive mechanical ventilation Patients with contraindications to receive dexamethasone or other corticosteroids |
| Dexamethasone | Recommended | 6 mg iv or per os daily for 10 days or until hospital discharge (whichever is first) | Patients with SpO2 ≤ 94 % on room air |
| Neutralizing antibodies (casirivimab/ imdevimab, or sotrovimab) | N/A | – | COVID-19 at high risk for progression |
| Remdesivir | Not recommended | 200 mg iv – 1st day one 100 mg iv daily - days 2−5 |
Patients with SpO2 ≤ 94 % on room air |
| Tocilizumab | Recommended | 4 – 8 mg/kg iv (single dose) | Patients with SpO2 ≤ 94 % on room air and CRP ≥ 75 mg/L |
| HCQ | Not recommended | N/A | N/A |